週四，Cronos Group Inc（納斯達克股票代碼：CRON）報告第四季度銷售額爲3030萬美元，高於上一季度的2392萬美元，但未達到市場預期的3495萬美元。同比增長主要由加拿大市場的大麻花和提取物銷售增加，以及以色列和其他國家的大麻花銷售增加所推動。Cronos GrowCo在2024年第四季度貢獻了210萬美元的大麻花銷售額。這家大麻素公司報告每股收益爲0.11美元，相較於上一季度每股虧損0.19美元。公司報告毛利潤爲1080萬美元，高於上一季度的191萬美元，主要由於銷售增加和生產成本改善。毛利潤受到了180萬美元的積極影響，這與Cronos GrowCo交易的購置會計最終確定有關，其導致從Cronos GrowCo獲取的庫存的公允價值減少以及之前記錄在銷售成本中的庫存階梯上升減少。此外，調整後的毛利潤爲900萬美元，比2023年第四季度改善了710萬美元。調整後的EBITDA虧損達到720萬美元，改善了760萬美元。主席、總裁兼CEO Mike Gorenstein表示：“Cronos有很好的定位能夠把握未來的機會，爲我們的股東創造長期價值。展望2025年，我們將繼續保持這種勢頭，鞏固我們的市場領導地位，並推出在全球範圍內深受消費者歡迎的創新產品。”他補充道：“我們的戰略投資，如Cronos GrowCo，增強了我們的種植能力，確保了高質量大麻的持續供應，並改善了毛利率，同時，我們的研發突破樹立了行業新標準。”

以上內容來自Benzinga Earnings專欄，原文如下：

On Thursday, Cronos Group Inc (NASDAQ:CRON) reported fourth-quarter sales of $30.3 million, up from $23.92 million, missing the consensus of $34.95 million.

The increase year-over-year was primarily driven by higher cannabis flower and extract sales in the Canadian market and higher cannabis flower sales in Israel and other countries.

Cronos GrowCo contributed $2.1 million of cannabis flower sales in Q4 2024.

The cannabinoid company reported earnings of 11 cents compared to a loss of 19 cents.

Also Next: Cronos CEO Mike Gorenstein Says He’s Optimistic About Trump’s Impact On Cannabis

The company reported a gross profit of $10.8 million, up from $1.91 million, primarily due to higher sales and production cost improvements. Gross profit was positively impacted by $1.8 million in the quarter in connection with the finalization of the purchase accounting for the Cronos GrowCo Transaction, which resulted in a reduction of the fair value of inventory acquired from Cronos GrowCo and the corresponding inventory step-up previously recorded into the cost of sales.

• Adjusted gross profit of $9.0 million, improved by $7.1 million from Q4 2023.

Adjusted EBITDA loss reached $7.2 million, an improvement of $7.6 million.

“Cronos is well-positioned to capitalize on future opportunities and drive long-term value for our shareholders. As we look ahead to 2025, we remain focused on sustaining this momentum, strengthening our market leadership, and delivering innovative products that resonate with consumers worldwide,” said Mike Gorenstein, chairman, president and CEO of Cronos.

“Our strategic investments, such as Cronos GrowCo, have enhanced our cultivation capabilities, ensuring a consistent supply of high-quality cannabis at scale with an improved gross margin profile, while our R&D breakthroughs have set new industry standards,” Gorenstein added.

Price Action: CRON stock is up 7.87% at $1.9 at the last check Thursday.

Read Next:

• Payoneer Q4: 17% Revenue Growth, $22.5 Billion In Transactions, B2B Payments Up 37%, Revenue Target Surges

Photo: Shutterstock